A PHASE 3 TRIAL COMPARING TALAZOPARIB, AN ORAL PARP INHIBITOR, TO PHYSICIAN'S CHOICE OF THERAPY IN PATIENTS WITH ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION: EMBRACA SUBGROUPS BY AGE

Yerushalmi Rinat; Eiermann Wolfgang; Rugo Hope; Ettl Johannes; Hurvitz Sara A.; Goncalves Anthony; Miguel Martin; Markova Denka; Tudors Iulia; Blum Joanne; Hannah Alison; Litton Jennifer

首页> 外文期刊>The Breast : >A PHASE 3 TRIAL COMPARING TALAZOPARIB, AN ORAL PARP INHIBITOR, TO PHYSICIAN'S CHOICE OF THERAPY IN PATIENTS WITH ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION: EMBRACA SUBGROUPS BY AGE

【24h】

A PHASE 3 TRIAL COMPARING TALAZOPARIB, AN ORAL PARP INHIBITOR, TO PHYSICIAN'S CHOICE OF THERAPY IN PATIENTS WITH ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION: EMBRACA SUBGROUPS BY AGE

机译：将Talazoparib，口服PARP抑制剂的第3阶段试验到医生在先进的乳腺癌患者和种系BRCA突变中选择治疗：Bullaca亚组按年龄

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Breast :》 |2018年第2018期|共1页
作者
Yerushalmi Rinat; Eiermann Wolfgang; Rugo Hope; Ettl Johannes; Hurvitz Sara A.; Goncalves Anthony; Miguel Martin; Markova Denka; Tudors Iulia; Blum Joanne; Hannah Alison; Litton Jennifer;
展开▼
作者单位

Beilinson Med Ctr Rabin Med Ctr Petah Tiqwa Israel;

Interdisziplinares Onkol Zentrum Munich Germany;

UCSF Helen Diller Family Comprehens Canc Ctr San Francisco CA USA;

Tech Univ Munich Dept Obstet &

Gynecol Klinikum Rechts Isar Munich Germany;

Univ Calif Los Angeles Los Angeles CA USA;

Inst Paoli Calmettes Marseille France;

Univ Complutense Inst Invest Sanitaria Gregorio Maranon CIBERONC GEICAM Madrid Spain;

Pfizer Global Biometr &

Data Management San Francisco CA USA;

Pfizer Global Biometr &

Data Management San Francisco CA USA;

Baylor Sammons Canc Ctr Texas Oncol US Oncol Dallas TX USA;

Pfizer Global Biometr &

Data Management San Francisco CA USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. A PHASE 3 TRIAL COMPARING TALAZOPARIB, AN ORAL PARP INHIBITOR, TO PHYSICIAN'S CHOICE OF THERAPY IN PATIENTS WITH ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION: EMBRACA SUBGROUPS BY AGE [J] . Yerushalmi Rinat, Eiermann Wolfgang, Rugo Hope, The Breast : . 2018,第Suppla1期

机译：将Talazoparib，口服PARP抑制剂的第3阶段试验到医生在先进的乳腺癌患者和种系BRCA突变中选择治疗：Bullaca亚组按年龄
2. A PHASE 3 TRIAL COMPARING TALAZOPARIB, AN ORAL PARP INHIBITOR, TO PHYSICIAN'S CHOICE OF THERAPY IN PATIENTS WITH ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION: EMBRACA SUBGROUPS BY AGE [J] . Yerushalmi Rinat, Eiermann Wolfgang, Rugo Hope, The Breast : . 2018,第期

机译：将Talazoparib，口服PARP抑制剂的第3阶段试验到医生在先进的乳腺癌患者和种系BRCA突变中选择治疗：Bullaca亚组按年龄
3. A PHASE 3 TRIAL COMPARING TALAZOPARIB, AN ORAL PARP INHIBITOR, TO PHYSICIAN'S CHOICE OF THERAPY IN PATIENTS WITH ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION: EMBRACA SUBGROUPS BY AGE [J] . Yerushalmi Rinat, Eiermann Wolfgang, Rugo Hope, The Breast : . 2018,第Suppla1期

机译：将Talazoparib，口服PARP抑制剂的第3阶段试验到医生在先进的乳腺癌患者和种系BRCA突变中选择治疗：Bullaca亚组按年龄
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. Phase I Dose-Escalation Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers [O] . Johann de Bono, Ramesh K. Ramanathan, Lida Mina, -1

机译：I期剂量递增的PARP抑制剂Talazoparib在晚期生殖系BRCA1 / 2突变和部分散发性癌症患者中进行两部分试验
6. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial [O] . J. Ettl, R.G.W. Quek, K.-H. Lee, 2018

机译：塔罗帕里布的生活质量与医生选择了先进的乳腺癌和种系BRCA1 / 2突变的患者的化疗：患者报告的来自HARMACA期III试验的结果

A PHASE 3 TRIAL COMPARING TALAZOPARIB, AN ORAL PARP INHIBITOR, TO PHYSICIAN'S CHOICE OF THERAPY IN PATIENTS WITH ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION: EMBRACA SUBGROUPS BY AGE

著录项

相似文献

相关主题

期刊订阅